In part 2 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the impact of PCSK9 inhibitor on cholesterol.

In this week's Homerun Slides, defining the extent of beta cell loss.

Glucose-lowering agents: Metformin is a biguanide that has been used worldwide for more than 50 years for the treatment of T2DM although its exact mechanism of action remains incompletely understood. It decreases hepatic glucose production and improves insulin sensitivity at the level of the liver, and to a lesser extent, muscle. Metformin has been reported to reduce plasma aminotransferase levels in patients with NAFLD. Early small studies suggested that metformin improved hepatic steatosis, necro-inflammation and/or fibrosis in patients with NASH, but not in more recent and better controlled clinical trials.

When is a disease not really a disease? The answer is simple: “when the disease is diabetes.” Over the past 40 years there has been great momentum on how to change the perception. We tried lowering the target fasting levels, A1c’s and PPG values and adding new medications and monitoring …

With millions of possible drug combinations for treatment of diabetes, hypertension, hyperlipidemia and heart disease, new AI program offers more thorough analysis and options.

Getting type 2 diabetes at an early age increases risk for all diabetes complications, including death.

Why patients are not seeing results when it comes to adhering to treatment plans.

How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.

Decades ago, going to an International Diabetic Athletes Association (IDAA) meeting in 1990 helped shaped the future direction of my career in diabetes and exercise. I remember talking with people about managing blood glucose with type 1 diabetes during activities of varying types and intensities, and my interest in compiling such useful information led to my first book attempting to create a guide for exercisers with diabetes in 2001. IDAA later became the Diabetes Exercise & Sports Association (DESA), and it later combined with InsulinDependence.org. Sadly, all those organizations are now defunct, the latest casualties of money problems that many not-for-profit organizations have experienced of late.

A 75-year-old man presents to your office with complaints of occasional mild hypoglycemia. His current antihyperglycemic regimen includes metformin and nateglinide. You would like to modify his treatment regimen to minimize his risk of hypoglycemia. Which one of the following 2-drug combinations would NOT be a suitable substitution? A. Metformin + pioglitazone B. Metformin + glipizide C. Metformin + vildaglipitin D. Metformin + exenatide Follow the link for the answer.